A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database

F Zou, C Zhu, S Lou, Z Cui, D Wang, Y Ou… - Frontiers in …, 2023 - frontiersin.org
Mepolizumab is primarily used in the treatment of asthma, eosinophilic granulomatosis with
polyangiitis, eosinophilia syndrome, and chronic rhinitis with nasal polyps. The information …

Fungal lung disease

TK Jaggi, R Agarwal, PY Tiew, A Shah… - European …, 2024 - publications.ersnet.org
Fungal lung disease encompasses a wide spectrum of organisms and associated clinical
conditions, presenting a significant global health challenge. The type and severity of disease …

Protocol for the systematic review of the Pneumocystis jirovecii-associated pneumonia in non-HIV immunocompromised patients

ME Orozco-Ugarriza, Y Olivo-Martínez… - Plos one, 2024 - journals.plos.org
Introduction Pneumocystis jirovecii pneumonia (PJP) is a well-known and frequent
opportunistic infection in HIV patients. However, there has been an increase in the number …

Immune checkpoint inhibitor increased mortality in lung cancer patients with Pneumocystis jirovecii pneumonia: a comparative retrospective cohort study

B Fan, X Sun, W Han, Y Zou, F Chen, F Lan… - Frontiers in …, 2024 - pmc.ncbi.nlm.nih.gov
Introduction Pneumocystis jirovecii pneumonia (PJP) is a life-threatening infection in
immunocompromised individuals. Immune checkpoint inhibitor (ICI) has brought significant …

Comprehensive analysis of adverse events associated with onasemnogene abeparvovec (Zolgensma) in spinal muscular atrophy patients: insights from FAERS …

W Zhang, Y Yin, D Yang, M Liu, C Ye… - Frontiers in …, 2025 - frontiersin.org
Onasemnogene Abeparvovec (Zolgensma) is a gene therapy for the treatment of Spinal
Muscular Atrophy (SMA) with improved motor neuron function and the potential for a …

Association between immune checkpoint inhibitor and cytomegalovirus infection: A pharmacovigilance study based on the adverse event reporting system

N Okada, T Yanagi, T Sasaki, M Tamura… - … Journal of Cancer, 2025 - Wiley Online Library
Immune checkpoint inhibitor (ICI)‐induced adverse events due to excessive immune
stimulation are problematic in immunotherapy. The activation of viral infection triggered by …

Comparisons of adverse events associated with immune checkpoint inhibitors in the treatment of non-small cell lung cancer: a real-world disproportionality analysis …

R Gao, W Liang, J Chen, M Yang, X Yu, X Wang - BMC cancer, 2025 - Springer
Background Immune checkpoint inhibitor (ICI) therapy is increasingly used to treat non-small
cell lung cancer (NSCLC). However, little attention has been given to the comparative …

Mining and analysis of dizziness adverse event signals in postoperative analgesia patients based on the FDA adverse event reporting system database

F Zhou, H He, Z Zhang, J Gao - Frontiers in Pharmacology, 2025 - frontiersin.org
Objective This study aimed to explore the association between drugs used in postoperative
anesthesia patients and postoperative dizziness using the US Food and Drug …

Model driven method for exploring individual and confounding effects in spontaneous adverse event reporting databases

B Lv, Y Li, A Shi, J Pan - Expert Opinion on Drug Safety, 2024 - Taylor & Francis
ABSTRACT Background Spontaneous Adverse Event Reporting (SAER) databases play a
crucial role in post-marketing drug surveillance. However, the traditional model-free …

[PDF][PDF] Pneumocystis jirovecii Pneumonia (PCP) in a Non-HIV Lung Cancer Patient in the Absence of Common Risk Factors

S Hashmi, D Yousuf, P Kumar - Cureus, 2023 - cureus.com
Pneumocystis jirovecii pneumonia (PCP) has been described mainly in AIDs and in
immunocompromised patients with hematological malignancies, organ transplant recipients …